In a therapeutic trial of chronic pancreatitis, oral administration of a CCKAR antagonist induced symptoms, such as abdominal fullness, diarrhea, and heartburn, in patients, although they were mild or moderate (Shiratori et al., 2002). Here, CCKAR is linked to chronic pancreatitis.